ZA200200939B - RAR selective retinoid agonists. - Google Patents
RAR selective retinoid agonists. Download PDFInfo
- Publication number
- ZA200200939B ZA200200939B ZA200200939A ZA200200939A ZA200200939B ZA 200200939 B ZA200200939 B ZA 200200939B ZA 200200939 A ZA200200939 A ZA 200200939A ZA 200200939 A ZA200200939 A ZA 200200939A ZA 200200939 B ZA200200939 B ZA 200200939B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- tetrahydrobenzo
- benzoic acid
- methoxymethyl
- compound
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title description 14
- 150000004492 retinoid derivatives Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 86
- 239000000203 mixture Substances 0.000 claims description 35
- 239000005711 Benzoic acid Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 206010014561 Emphysema Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229920002554 vinyl polymer Polymers 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000002585 base Substances 0.000 claims description 7
- 235000010233 benzoic acid Nutrition 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 150000001735 carboxylic acids Chemical class 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- VOFMOBJODDPURX-AATRIKPKSA-N 4-[(e)-2-[5-(ethoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzothiepin-8-yl]ethenyl]benzoic acid Chemical compound C=1C=C2C(COCC)(C)CCCSC2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 VOFMOBJODDPURX-AATRIKPKSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 5
- CTURAYFRAMCQLH-BJILWQEISA-N COCC1(CCOC2=CC=C(C=C12)/C=C/C1=CC=C(C(=O)O)C=C1)C.COCC1(CCOC2=CC=C(C=C12)C#CC1=CC=C(C(=O)O)C=C1)C Chemical compound COCC1(CCOC2=CC=C(C=C12)/C=C/C1=CC=C(C(=O)O)C=C1)C.COCC1(CCOC2=CC=C(C=C12)C#CC1=CC=C(C(=O)O)C=C1)C CTURAYFRAMCQLH-BJILWQEISA-N 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 102
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 99
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 37
- 229940093499 ethyl acetate Drugs 0.000 description 36
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- 239000012074 organic phase Substances 0.000 description 34
- 229960004132 diethyl ether Drugs 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000002904 solvent Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- 238000003818 flash chromatography Methods 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000004817 gas chromatography Methods 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 21
- 235000019341 magnesium sulphate Nutrition 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000012230 colorless oil Substances 0.000 description 20
- 108090000064 retinoic acid receptors Proteins 0.000 description 20
- 102000003702 retinoic acid receptors Human genes 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 238000001914 filtration Methods 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- -1 tert.-butyl Chemical group 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 10
- 229930002330 retinoic acid Natural products 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 229910052681 coesite Inorganic materials 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 229910052906 cristobalite Inorganic materials 0.000 description 6
- 230000005595 deprotonation Effects 0.000 description 6
- 238000010537 deprotonation reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 229910052682 stishovite Inorganic materials 0.000 description 6
- 229910052905 tridymite Inorganic materials 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003138 primary alcohols Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 102000034527 Retinoid X Receptors Human genes 0.000 description 4
- 108010038912 Retinoid X Receptors Proteins 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 4
- OMHQJHQNQVNLEV-UHFFFAOYSA-N (4-methyl-2,3-dihydrochromen-4-yl)methanol Chemical compound C1=CC=C2C(C)(CO)CCOC2=C1 OMHQJHQNQVNLEV-UHFFFAOYSA-N 0.000 description 3
- BRTQCMQWIFSHAN-UHFFFAOYSA-N (8-bromo-5-methyl-3,4-dihydro-2h-1-benzothiepin-5-yl)methanol Chemical compound OCC1(C)CCCSC2=CC(Br)=CC=C12 BRTQCMQWIFSHAN-UHFFFAOYSA-N 0.000 description 3
- SOHIYESEPVZKHS-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxepine Chemical class C1CCC=COC1 SOHIYESEPVZKHS-UHFFFAOYSA-N 0.000 description 3
- GIANSFFRJWVAIK-UHFFFAOYSA-N 4-[2-[4-(methoxymethyl)-4-methyl-2,3-dihydrochromen-6-yl]ethynyl]benzoic acid Chemical compound C1=C2C(COC)(C)CCOC2=CC=C1C#CC1=CC=C(C(O)=O)C=C1 GIANSFFRJWVAIK-UHFFFAOYSA-N 0.000 description 3
- DOOAJHWQKPGEHC-UHFFFAOYSA-N 8-bromo-5-(ethoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzothiepine Chemical compound CCOCC1(C)CCCSC2=CC(Br)=CC=C12 DOOAJHWQKPGEHC-UHFFFAOYSA-N 0.000 description 3
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960001445 alitretinoin Drugs 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009786 epithelial differentiation Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- BZQJORBFRHWNDM-UHFFFAOYSA-N (4-methyl-2,3-dihydrochromen-4-yl)methyl acetate Chemical compound C1=CC=C2C(COC(=O)C)(C)CCOC2=C1 BZQJORBFRHWNDM-UHFFFAOYSA-N 0.000 description 2
- GICWOWRUIGCEEE-UHFFFAOYSA-N (6-bromo-4-methyl-2,3-dihydrochromen-4-yl)methyl acetate Chemical compound C1=C(Br)C=C2C(COC(=O)C)(C)CCOC2=C1 GICWOWRUIGCEEE-UHFFFAOYSA-N 0.000 description 2
- FEAAKHIPVPHDGC-UHFFFAOYSA-N (6-ethynyl-4-methyl-2,3-dihydrochromen-4-yl)methyl acetate Chemical compound C1=C(C#C)C=C2C(COC(=O)C)(C)CCOC2=C1 FEAAKHIPVPHDGC-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- MICTUIBIFKCHCY-UHFFFAOYSA-N 2-[4-(methoxymethyl)-4-methyl-2,3-dihydrochromen-6-yl]ethynyl-trimethylsilane Chemical compound C1=C(C#C[Si](C)(C)C)C=C2C(COC)(C)CCOC2=C1 MICTUIBIFKCHCY-UHFFFAOYSA-N 0.000 description 2
- GSEOHUUQFIJCPA-UHFFFAOYSA-N 4-(methoxymethyl)-4-methyl-2,3-dihydrochromene Chemical compound C1=CC=C2C(COC)(C)CCOC2=C1 GSEOHUUQFIJCPA-UHFFFAOYSA-N 0.000 description 2
- IXBTUGFYHVZLLP-AATRIKPKSA-N 4-[(e)-2-[5-methyl-5-(propoxymethyl)-3,4-dihydro-2h-1-benzoxepin-8-yl]ethenyl]benzoic acid Chemical compound C=1C=C2C(COCCC)(C)CCCOC2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 IXBTUGFYHVZLLP-AATRIKPKSA-N 0.000 description 2
- SEDHSETVCZKXNR-UHFFFAOYSA-N 4-[2-[5-(methoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzothiepin-8-yl]ethynyl]benzoic acid Chemical compound C=1C=C2C(COC)(C)CCCSC2=CC=1C#CC1=CC=C(C(O)=O)C=C1 SEDHSETVCZKXNR-UHFFFAOYSA-N 0.000 description 2
- XUNWKZCNCGPGOP-UHFFFAOYSA-N 4-methyl-2,3-dihydrochromene-4-carbaldehyde Chemical compound C1=CC=C2C(C)(C=O)CCOC2=C1 XUNWKZCNCGPGOP-UHFFFAOYSA-N 0.000 description 2
- MFSOSUFMFBDJRW-UHFFFAOYSA-N 5-(ethoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzothiepine-8-carbaldehyde Chemical compound CCOCC1(C)CCCSC2=CC(C=O)=CC=C12 MFSOSUFMFBDJRW-UHFFFAOYSA-N 0.000 description 2
- XSOVIAWIIMVIGI-UHFFFAOYSA-N 5-(methoxymethyl)-5-propyl-3,4-dihydro-2h-1-benzoxepine-8-carbaldehyde Chemical compound CCCC1(COC)CCCOC2=CC(C=O)=CC=C12 XSOVIAWIIMVIGI-UHFFFAOYSA-N 0.000 description 2
- WYSQKJSUCVWCPP-UHFFFAOYSA-N 6-bromo-4-(methoxymethyl)-4-methyl-2,3-dihydrochromene Chemical compound C1=C(Br)C=C2C(COC)(C)CCOC2=C1 WYSQKJSUCVWCPP-UHFFFAOYSA-N 0.000 description 2
- WYOZOOHMOLFSDJ-UHFFFAOYSA-N 6-ethynyl-4-(methoxymethyl)-4-methyl-2,3-dihydrochromene Chemical compound C1=C(C#C)C=C2C(COC)(C)CCOC2=C1 WYOZOOHMOLFSDJ-UHFFFAOYSA-N 0.000 description 2
- AKSLKUOXOIRZBA-UHFFFAOYSA-N 8-bromo-2,3,4,5-tetrahydro-1-benzoxepine-5-carbaldehyde Chemical compound O=CC1CCCOC2=CC(Br)=CC=C21 AKSLKUOXOIRZBA-UHFFFAOYSA-N 0.000 description 2
- QNLKNFSEQSCQRR-UHFFFAOYSA-N 8-bromo-3,4-dihydro-2h-1-benzothiepin-5-one Chemical compound S1CCCC(=O)C=2C1=CC(Br)=CC=2 QNLKNFSEQSCQRR-UHFFFAOYSA-N 0.000 description 2
- VUIYYTWSPPVDTD-UHFFFAOYSA-N 8-bromo-5-(methoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzothiepine Chemical compound COCC1(C)CCCSC2=CC(Br)=CC=C12 VUIYYTWSPPVDTD-UHFFFAOYSA-N 0.000 description 2
- VNXJGYRDJDBASA-UHFFFAOYSA-N 8-bromo-5-(methoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzoxepine Chemical compound COCC1(C)CCCOC2=CC(Br)=CC=C12 VNXJGYRDJDBASA-UHFFFAOYSA-N 0.000 description 2
- NWDCESXTFQUVNX-UHFFFAOYSA-N 8-bromo-5-(methoxymethyl)-5-propyl-3,4-dihydro-2h-1-benzoxepine Chemical compound CCCC1(COC)CCCOC2=CC(Br)=CC=C12 NWDCESXTFQUVNX-UHFFFAOYSA-N 0.000 description 2
- SFRQRFWLXBBTFR-UHFFFAOYSA-N 8-ethynyl-5-(methoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzoxepine Chemical compound COCC1(C)CCCOC2=CC(C#C)=CC=C12 SFRQRFWLXBBTFR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000001351 alkyl iodides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 229940125890 compound Ia Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 150000002084 enol ethers Chemical class 0.000 description 2
- 230000009841 epithelial lesion Effects 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- OFUCEQWVGVURAS-UHFFFAOYSA-N ethyl 4-(diethoxyphosphorylmethyl)benzoate Chemical compound CCOC(=O)C1=CC=C(CP(=O)(OCC)OCC)C=C1 OFUCEQWVGVURAS-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- GOUOELTUEQQRRT-UHFFFAOYSA-N methyl 4-[2-[4-(methoxymethyl)-4-methyl-2,3-dihydrochromen-6-yl]ethynyl]benzoate Chemical compound C1=C2C(COC)(C)CCOC2=CC=C1C#CC1=CC=C(C(=O)OC)C=C1 GOUOELTUEQQRRT-UHFFFAOYSA-N 0.000 description 2
- HOSOOSDBTVRIGX-UHFFFAOYSA-N methyl 4-[2-[5-(methoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzoxepin-8-yl]ethynyl]benzoate Chemical compound C=1C=C2C(COC)(C)CCCOC2=CC=1C#CC1=CC=C(C(=O)OC)C=C1 HOSOOSDBTVRIGX-UHFFFAOYSA-N 0.000 description 2
- DYUWQWMXZHDZOR-UHFFFAOYSA-N methyl 4-iodobenzoate Chemical compound COC(=O)C1=CC=C(I)C=C1 DYUWQWMXZHDZOR-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- DLAXCQFAFHBMJY-UHFFFAOYSA-N (8-bromo-5-methyl-3,4-dihydro-2h-1-benzoxepin-5-yl)methanol Chemical compound OCC1(C)CCCOC2=CC(Br)=CC=C12 DLAXCQFAFHBMJY-UHFFFAOYSA-N 0.000 description 1
- JPHAQKNEDMRMFM-UHFFFAOYSA-N (8-bromo-5-propyl-3,4-dihydro-2h-1-benzoxepin-5-yl)methanol Chemical compound CCCC1(CO)CCCOC2=CC(Br)=CC=C12 JPHAQKNEDMRMFM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- CIJBRVFURVUXMM-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1-benzothiepin-2-ylmethanol Chemical compound S1C(CO)CCCC2=CC=CC=C21 CIJBRVFURVUXMM-UHFFFAOYSA-N 0.000 description 1
- XNMYBTLKAQPVQT-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1-benzoxepin-2-ylmethanol Chemical compound O1C(CO)CCCC2=CC=CC=C21 XNMYBTLKAQPVQT-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- RUHDMIRVAFTNRL-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)CCOC2=C1 RUHDMIRVAFTNRL-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- HNGQQUDFJDROPY-UHFFFAOYSA-N 3-bromobenzenethiol Chemical compound SC1=CC=CC(Br)=C1 HNGQQUDFJDROPY-UHFFFAOYSA-N 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- ZDIBKEWYZLHOJX-ONEGZZNKSA-N 4-[(e)-2-[4-(methoxymethyl)-4-methyl-2,3-dihydrochromen-6-yl]ethenyl]benzoic acid Chemical compound C1=C2C(COC)(C)CCOC2=CC=C1\C=C\C1=CC=C(C(O)=O)C=C1 ZDIBKEWYZLHOJX-ONEGZZNKSA-N 0.000 description 1
- AQRRFBSTUODWOG-SNAWJCMRSA-N 4-[(e)-2-[5-(methoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzoxepin-8-yl]ethenyl]benzoic acid Chemical compound C=1C=C2C(COC)(C)CCCOC2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 AQRRFBSTUODWOG-SNAWJCMRSA-N 0.000 description 1
- SXVOHIMDGSABTF-AATRIKPKSA-N 4-[(e)-2-[5-(methoxymethyl)-5-propyl-3,4-dihydro-2h-1-benzothiepin-8-yl]ethenyl]benzoic acid Chemical compound C=1C=C2C(CCC)(COC)CCCSC2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 SXVOHIMDGSABTF-AATRIKPKSA-N 0.000 description 1
- ZMAXJHXSMOYDIW-AATRIKPKSA-N 4-[(e)-2-[5-(methoxymethyl)-5-propyl-3,4-dihydro-2h-1-benzoxepin-8-yl]ethenyl]benzoic acid Chemical compound C=1C=C2C(CCC)(COC)CCCOC2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 ZMAXJHXSMOYDIW-AATRIKPKSA-N 0.000 description 1
- FDCUAHFXAPNSJR-UHFFFAOYSA-N 4-[2-[4-(acetyloxymethyl)-4-methyl-2,3-dihydrochromen-6-yl]ethynyl]benzoic acid Chemical compound C1=C2C(COC(=O)C)(C)CCOC2=CC=C1C#CC1=CC=C(C(O)=O)C=C1 FDCUAHFXAPNSJR-UHFFFAOYSA-N 0.000 description 1
- CZZRYJSFDKYTRX-UHFFFAOYSA-N 4-[2-[4-(hydroxymethyl)-4-methyl-2,3-dihydrochromen-6-yl]ethynyl]benzoic acid Chemical compound C1=C2C(C)(CO)CCOC2=CC=C1C#CC1=CC=C(C(O)=O)C=C1 CZZRYJSFDKYTRX-UHFFFAOYSA-N 0.000 description 1
- OZCNOMNNLZGXAG-UHFFFAOYSA-N 4-[2-[5-(ethoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzoxepin-8-yl]ethynyl]benzoic acid Chemical compound C=1C=C2C(COCC)(C)CCCOC2=CC=1C#CC1=CC=C(C(O)=O)C=C1 OZCNOMNNLZGXAG-UHFFFAOYSA-N 0.000 description 1
- PTAKZNJIEZJKPN-UHFFFAOYSA-N 4-[2-[5-methyl-5-(propoxymethyl)-3,4-dihydro-2h-1-benzoxepin-8-yl]ethynyl]benzoic acid Chemical compound C=1C=C2C(COCCC)(C)CCCOC2=CC=1C#CC1=CC=C(C(O)=O)C=C1 PTAKZNJIEZJKPN-UHFFFAOYSA-N 0.000 description 1
- LPAYXXMXEJUGQM-UHFFFAOYSA-N 5-(methoxymethyl)-5-propyl-3,4-dihydro-2h-1-benzothiepine-8-carbaldehyde Chemical compound CCCC1(COC)CCCSC2=CC(C=O)=CC=C12 LPAYXXMXEJUGQM-UHFFFAOYSA-N 0.000 description 1
- RYBRYYPJUGXFCY-UHFFFAOYSA-N 6-bromo-4-(methoxymethyl)-4-methyl-2,3-dihydrochromene;8-bromo-5-(methoxymethyl)-5-propyl-3,4-dihydro-2h-1-benzoxepine Chemical compound C1=C(Br)C=C2C(COC)(C)CCOC2=C1.CCCC1(COC)CCCOC2=CC(Br)=CC=C12 RYBRYYPJUGXFCY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- PCPUAZRWCCHSFF-UHFFFAOYSA-N 8-bromo-2,3,4,5-tetrahydro-1-benzothiepine-5-carbaldehyde Chemical compound O=CC1CCCSC2=CC(Br)=CC=C21 PCPUAZRWCCHSFF-UHFFFAOYSA-N 0.000 description 1
- LXKQMHNFHKVGAZ-UHFFFAOYSA-N 8-bromo-3,4-dihydro-2h-1-benzoxepin-5-one Chemical compound O1CCCC(=O)C=2C1=CC(Br)=CC=2 LXKQMHNFHKVGAZ-UHFFFAOYSA-N 0.000 description 1
- MMZHELJAIITTFP-UHFFFAOYSA-N 8-bromo-5-(methoxymethylidene)-3,4-dihydro-2h-1-benzothiepine Chemical compound COC=C1CCCSC2=CC(Br)=CC=C12 MMZHELJAIITTFP-UHFFFAOYSA-N 0.000 description 1
- HALFPIJMTYSADV-UHFFFAOYSA-N 8-bromo-5-methyl-3,4-dihydro-2h-1-benzothiepine-5-carbaldehyde Chemical compound O=CC1(C)CCCSC2=CC(Br)=CC=C12 HALFPIJMTYSADV-UHFFFAOYSA-N 0.000 description 1
- YIZLHAVMCHAQOP-UHFFFAOYSA-N 8-bromo-5-methyl-3,4-dihydro-2h-1-benzoxepine-5-carbaldehyde Chemical compound O=CC1(C)CCCOC2=CC(Br)=CC=C12 YIZLHAVMCHAQOP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100022941 Retinol-binding protein 1 Human genes 0.000 description 1
- 108050008744 Retinol-binding protein 1 Proteins 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- XCTPTRZUUVGEAP-UHFFFAOYSA-N [4-methyl-6-(2-trimethylsilylethynyl)-2,3-dihydrochromen-4-yl]methyl acetate Chemical compound C1=C(C#C[Si](C)(C)C)C=C2C(COC(=O)C)(C)CCOC2=C1 XCTPTRZUUVGEAP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- SYESMXTWOAQFET-YCNIQYBTSA-N all-trans-3,4-didehydroretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CCC1(C)C SYESMXTWOAQFET-YCNIQYBTSA-N 0.000 description 1
- GGCUJPCCTQNTJF-FRCNGJHJSA-N all-trans-4-oxoretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C GGCUJPCCTQNTJF-FRCNGJHJSA-N 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000008382 alveolar damage Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- GOHCTCOGYKAJLZ-UHFFFAOYSA-N ctep Chemical compound CC=1N(C=2C=CC(OC(F)(F)F)=CC=2)C(C)=NC=1C#CC1=CC=NC(Cl)=C1 GOHCTCOGYKAJLZ-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- WPSFEXSPQCXGAB-BQYQJAHWSA-N ethyl 4-[(e)-2-[5-(methoxymethyl)-5-propyl-3,4-dihydro-2h-1-benzoxepin-8-yl]ethenyl]benzoate Chemical compound C=1C=C2C(CCC)(COC)CCCOC2=CC=1\C=C\C1=CC=C(C(=O)OCC)C=C1 WPSFEXSPQCXGAB-BQYQJAHWSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RTTDYMSMJLCBQD-VOTSOKGWSA-N methyl 4-[(e)-2-[5-(ethoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzothiepin-8-yl]ethenyl]benzoate Chemical compound C=1C=C2C(COCC)(C)CCCSC2=CC=1\C=C\C1=CC=C(C(=O)OC)C=C1 RTTDYMSMJLCBQD-VOTSOKGWSA-N 0.000 description 1
- KQYMRQNQBWEOLO-UHFFFAOYSA-N methyl 4-[2-[4-(acetyloxymethyl)-4-methyl-2,3-dihydrochromen-6-yl]ethynyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C#CC1=CC=C(OCCC2(COC(C)=O)C)C2=C1 KQYMRQNQBWEOLO-UHFFFAOYSA-N 0.000 description 1
- LXTTYXBNOVPKKY-UHFFFAOYSA-N methyl 4-[2-[5-(methoxymethyl)-5-methyl-3,4-dihydro-2h-1-benzothiepin-8-yl]ethynyl]benzoate Chemical compound C=1C=C2C(COC)(C)CCCSC2=CC=1C#CC1=CC=C(C(=O)OC)C=C1 LXTTYXBNOVPKKY-UHFFFAOYSA-N 0.000 description 1
- JPGRSTBIEYGVNO-UHFFFAOYSA-N methyl 4-ethynylbenzoate Chemical compound COC(=O)C1=CC=C(C#C)C=C1 JPGRSTBIEYGVNO-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- JJYKJUXBWFATTE-UHFFFAOYSA-N mosher's acid Chemical compound COC(C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000003537 structural cell Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99116603 | 1999-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200200939B true ZA200200939B (en) | 2003-07-30 |
Family
ID=8238844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200200939A ZA200200939B (en) | 1999-08-25 | 2002-02-01 | RAR selective retinoid agonists. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6479670B1 (de) |
| EP (1) | EP1212316B1 (de) |
| JP (1) | JP3795394B2 (de) |
| KR (1) | KR100470500B1 (de) |
| CN (1) | CN1151144C (de) |
| AR (1) | AR025351A1 (de) |
| AT (1) | ATE252093T1 (de) |
| AU (1) | AU769784B2 (de) |
| BR (1) | BR0013582A (de) |
| CA (1) | CA2382527A1 (de) |
| DE (1) | DE60005980T2 (de) |
| DK (1) | DK1212316T3 (de) |
| ES (1) | ES2207548T3 (de) |
| MX (1) | MXPA02001939A (de) |
| PT (1) | PT1212316E (de) |
| TR (1) | TR200200473T2 (de) |
| WO (1) | WO2001014360A2 (de) |
| ZA (1) | ZA200200939B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627651B1 (en) * | 1999-05-07 | 2003-09-30 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| JO2178B1 (en) * | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of invasive diseases, using selected anti-PAR materials |
| AU1888101A (en) * | 1999-12-13 | 2001-06-18 | Chugai Seiyaku Kabushiki Kaisha | 3-methyl-chroman and -thiochroman derivatives |
| BR0213501A (pt) * | 2001-11-02 | 2004-08-24 | Searle Llc | Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato |
| US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| AU2003286245A1 (en) * | 2002-11-25 | 2004-06-18 | Amedis Pharmaceuticals Ltd. | Silicon compounds to be used as ligands for retinoid receptors |
| ATE493091T1 (de) * | 2004-03-30 | 2011-01-15 | Proxy Biomedical Ltd | Behandeltes chirurgisches mesh aus monofilen fasern |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US10500232B2 (en) | 2013-08-26 | 2019-12-10 | The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone | Small molecule cellular reprogramming to generate neuronal cells |
| EP3348279B1 (de) | 2015-09-10 | 2021-08-04 | National University Corporation Okayama University | Medizinische zusammensetzung zur prävention oder behandlung von entzündlichen atemwegserkrankungen |
| CN107176945B (zh) * | 2016-03-11 | 2021-06-08 | 中国科学院上海有机化学研究所 | 一种视黄酸类化合物、其制备方法、中间体及应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
-
2000
- 2000-07-12 US US09/614,331 patent/US6479670B1/en not_active Expired - Fee Related
- 2000-08-18 AU AU69971/00A patent/AU769784B2/en not_active Ceased
- 2000-08-18 TR TR2002/00473T patent/TR200200473T2/xx unknown
- 2000-08-18 EP EP00958468A patent/EP1212316B1/de not_active Expired - Lifetime
- 2000-08-18 BR BR0013582-8A patent/BR0013582A/pt not_active IP Right Cessation
- 2000-08-18 DE DE60005980T patent/DE60005980T2/de not_active Expired - Fee Related
- 2000-08-18 PT PT00958468T patent/PT1212316E/pt unknown
- 2000-08-18 AT AT00958468T patent/ATE252093T1/de not_active IP Right Cessation
- 2000-08-18 CN CNB00811899XA patent/CN1151144C/zh not_active Expired - Fee Related
- 2000-08-18 DK DK00958468T patent/DK1212316T3/da active
- 2000-08-18 KR KR10-2002-7002458A patent/KR100470500B1/ko not_active IP Right Cessation
- 2000-08-18 JP JP2001518447A patent/JP3795394B2/ja not_active Expired - Fee Related
- 2000-08-18 ES ES00958468T patent/ES2207548T3/es not_active Expired - Lifetime
- 2000-08-18 CA CA002382527A patent/CA2382527A1/en not_active Abandoned
- 2000-08-18 WO PCT/EP2000/008065 patent/WO2001014360A2/en active IP Right Grant
- 2000-08-18 MX MXPA02001939A patent/MXPA02001939A/es active IP Right Grant
- 2000-08-23 AR ARP000104344A patent/AR025351A1/es not_active Application Discontinuation
-
2002
- 2002-02-01 ZA ZA200200939A patent/ZA200200939B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60005980D1 (de) | 2003-11-20 |
| WO2001014360A3 (en) | 2001-05-17 |
| CA2382527A1 (en) | 2001-03-01 |
| WO2001014360A2 (en) | 2001-03-01 |
| PT1212316E (pt) | 2004-02-27 |
| BR0013582A (pt) | 2002-05-07 |
| ES2207548T3 (es) | 2004-06-01 |
| EP1212316B1 (de) | 2003-10-15 |
| MXPA02001939A (es) | 2002-08-20 |
| JP2003507465A (ja) | 2003-02-25 |
| ATE252093T1 (de) | 2003-11-15 |
| CN1370156A (zh) | 2002-09-18 |
| AR025351A1 (es) | 2002-11-20 |
| AU6997100A (en) | 2001-03-19 |
| DE60005980T2 (de) | 2004-08-12 |
| AU769784B2 (en) | 2004-02-05 |
| KR20020039335A (ko) | 2002-05-25 |
| EP1212316A2 (de) | 2002-06-12 |
| DK1212316T3 (da) | 2004-02-23 |
| US6479670B1 (en) | 2002-11-12 |
| JP3795394B2 (ja) | 2006-07-12 |
| CN1151144C (zh) | 2004-05-26 |
| TR200200473T2 (tr) | 2002-05-21 |
| KR100470500B1 (ko) | 2005-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU772551B2 (en) | New selective retinoid agonists | |
| EP1280757B1 (de) | Gamma-selektive retinoide | |
| EP1212316B1 (de) | Benzopyran und benzothiopyran, verwendbar als selektive retinoid-agonisten | |
| AU2001289619B2 (en) | Thiophene retinoids | |
| AU2001289619A1 (en) | Thiophene retinoids |